Related references
Note: Only part of the references are listed.Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested AgainstPseudomonas aeruginosaandKlebsiella pneumoniaeIsolates from United States Medical Centers in 2016-2018
Helio S. Sader et al.
MICROBIAL DRUG RESISTANCE (2021)
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis
Patrick J. Nolan et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
Ana Paula Streling et al.
CLINICAL INFECTIOUS DISEASES (2021)
Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa
Michelle Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients
Barbara Balandin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam
Abigail M. Rubio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Efficacy assessment of PEV2 phage on Galleria mellonella larvae infected with a Pseudomonas aeruginosa dog otitis isolate
C. Antoine et al.
RESEARCH IN VETERINARY SCIENCE (2021)
Real-world use of ceftolozane/tazobactam: a systematic literature review
Laura Puzniak et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2021)
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
Christian M. Gill et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence
Raid Recio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and lsogenic β-Lactam-Resistant Mutants
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017
James A. Karlowsky et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
Antonio Vena et al.
CLINICAL INFECTIOUS DISEASES (2020)
In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017
Sibylle H. Lob et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2020)
Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
Alejandro Iregui et al.
MICROBIAL DRUG RESISTANCE (2020)
Resistance to ceftazidime-avibactam and underlying mechanisms
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States
Saima Aslam et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
Marianna Criscuolo et al.
ANTIBIOTICS-BASEL (2020)
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
Marta Francesca Di Pasquale et al.
CLINICAL INFECTIOUS DISEASES (2019)
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV
Scott R. Evans et al.
CLINICAL INFECTIOUS DISEASES (2019)
Challenges in severe community-acquired pneumonia: a point-of-view review
Antoni Torres et al.
INTENSIVE CARE MEDICINE (2019)
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients
Rachel Yoon Kyung Chang et al.
AAPS JOURNAL (2019)
Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient
Nancy Law et al.
INFECTION (2019)
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
Jose-Manuel Ortiz de la Rosa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa
Krisztina M. Papp-Wallace et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Bacteriophage Therapy of Chronic Nonhealing Wound: Clinical Study
Pooja Gupta et al.
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS (2019)
Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
Sandra Mikhail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
Katherine Young et al.
BMC MICROBIOLOGY (2019)
Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States
Y. P. Tabak et al.
JOURNAL OF HOSPITAL INFECTION (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam
Olga Rodriguez-Nunez et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
CLINICAL INFECTIOUS DISEASES (2019)
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
Delaney E Hart et al.
Open Forum Infectious Diseases (2019)
2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia
Matthew Mills et al.
Open Forum Infectious Diseases (2019)
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Zheng Pang et al.
BIOTECHNOLOGY ADVANCES (2019)
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial
Patrick Jault et al.
LANCET INFECTIOUS DISEASES (2019)
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
Sameer S. Kadri et al.
CLINICAL INFECTIOUS DISEASES (2018)
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
Laura Escola-Verge et al.
INFECTION (2018)
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
Gregory G. Stone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis
Gowri Raman et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2018)
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
Manuel Diaz-Canestro et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2018)
The PqsE and RhlR proteins are an autoinducer synthase-receptor pair that control virulence and biofilm development in Pseudomonas aeruginosa
Sampriti Mukherjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Role of the Multidrug Resistance Efflux Pump MexCD-OprJ in the Pseudomonas aeruginosa Quorum Sensing Response
Manuel Alcalde-Rico et al.
FRONTIERS IN MICROBIOLOGY (2018)
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Akinobu Ito et al.
Open Forum Infectious Diseases (2018)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
Jason C. Gallagher et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria
Vincent H. Tam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Structure, function and regulation of Pseudomonas aeruginosa porins
Sylvie Chevalier et al.
FEMS MICROBIOLOGY REVIEWS (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
Contribution of mexAB-oprM and mexXY (-oprA) efflux operons in antibiotic resistance of clinical Pseudomonas aeruginosa isolates in Tabriz, Iran
Hamid Reza Goli et al.
INFECTION GENETICS AND EVOLUTION (2016)
Adaptive resistance to antibiotics in bacteria: a systems biology perspective
Santiago Sandoval-Motta et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2016)
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
Jose A. Hidalgo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections
Stephanie E. Giancola et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Benjamin K. Chan et al.
SCIENTIFIC REPORTS (2016)
Mechanisms of Antibiotic Resistance
Jose M. Munita et al.
MICROBIOLOGY SPECTRUM (2016)
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
M. Berrazeg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination
Jonathan C. Cho et al.
PHARMACOTHERAPY (2015)
Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa
Juerg Dreier et al.
FRONTIERS IN MICROBIOLOGY (2015)
Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
Marisa L. Winkler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa
Duck Jin Hong et al.
INFECTION AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam: A Novel Cephalosporin/beta-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2014)
OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China
Zhi-li Fang et al.
INFECTION GENETICS AND EVOLUTION (2014)
Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards the development of novel anti-biofilm therapies
Patrick K. Taylor et al.
JOURNAL OF BIOTECHNOLOGY (2014)
Bacterial Persister Cell Formation and Dormancy
Thomas K. Wood et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2013)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Pranita D. Tamma et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance
Lucia Fernandez et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies
Hui Li et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control
Steven T. Rutherford et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection
E-J Joo et al.
INFECTION (2011)
Health Care-Associated Pneumonia (HCAP) Empiric Antibiotics Targeting Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa Predict Optimal Outcome
Scott T. Micek et al.
MEDICINE (2011)
Pseudomonas aeruginosa: all roads lead to resistance
Elena B. M. Breidenstein et al.
TRENDS IN MICROBIOLOGY (2011)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor
Therese Stachyra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Phage Therapy in Clinical Practice: Treatment of Human Infections
Elizabeth Kutter et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2010)
Aminoglycoside modifying enzymes
Maria S. Ramirez et al.
DRUG RESISTANCE UPDATES (2010)
Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study
M. Montero et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2010)
Emergence of Pseudomonas aeruginosa Strains Producing High Levels of Persister Cells in Patients with Cystic Fibrosis
Lawrence R. Mulcahy et al.
JOURNAL OF BACTERIOLOGY (2010)
Resistance mechanisms of multiresistant pseudomonas aeruginosa strains from Germany and correlation with Hypermutationdel
B. Henrichfreise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections:: Impact of delayed appropriate antibiotic selection
Thomas P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance
Thomas P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa
P Dupont et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
[Anonymous]
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Population and evolutionary dynamics of phage therapy
BR Levin et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Antimicrobial resistance of Pseudomonas aeruginosa biofilms
E Drenkard
MICROBES AND INFECTION (2003)
Pathophysiology and management of pulmonary infections in cystic fibrosis
RL Gibson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds
K Markoishvili et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2002)
Lung infections associated with cystic fibrosis
JB Lyczak et al.
CLINICAL MICROBIOLOGY REVIEWS (2002)
Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis
GB Pier et al.
INFECTION AND IMMUNITY (2001)
Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals
RJH Payne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
